What's the Value of Conferences?

FEATUREScientific Meetings   What's the Value of Conferences? A Keystone Symposia survey says: $20-30 million in research fund savingsBY JAMES W. AIKENThe long reach of Bill Gates finally touched the Keystone Symposia, and all of conference planning, really. I was writing a grant proposal for the Bill & Melinda Gates Foundation and came to an interesting stipulation: We had to show measured value for our program. Another routine survey

Written byJames W. Aiken
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

A Keystone Symposia survey says: $20-30 million in research fund savings

The long reach of Bill Gates finally touched the Keystone Symposia, and all of conference planning, really. I was writing a grant proposal for the Bill & Melinda Gates Foundation and came to an interesting stipulation: We had to show measured value for our program. Another routine survey where respondents write in what they liked and didn't like about our meetings clearly wouldn't do. I had to propose a method for quantitative assessment of the impact of our conferences. Our stated goals are to connect the scientific community for the benefit of society as well as catalyze scientific progress by having the highest quality programs - all well and good, but how to measure this?

To answer the question, we put together a survey that was conducted over two seasons of Keystone Symposia's meetings: winter/spring 2004 and winter/spring 2005. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies